Last reviewed · How we verify
INF1.0 + IBU
INF1.0 + IBU is a Interferon alfa + NSAID combination Small molecule drug developed by St. Justine's Hospital. It is currently FDA-approved for Viral infections (specific indication not clearly documented in available sources).
INF1.0 + IBU is a combination of interferon alfa-1b and ibuprofen that combines antiviral/immunomodulatory effects with anti-inflammatory and analgesic activity.
INF1.0 is a small molecule that, when combined with ibuprofen, is being studied in a clinical trial for pain management in children with a suspected fracture. This combination, known as INF1.0 + IBU, is being investigated in a randomized controlled trial at St. Justine's Hospital.
At a glance
| Generic name | INF1.0 + IBU |
|---|---|
| Sponsor | St. Justine's Hospital |
| Drug class | Interferon alfa + NSAID combination |
| Target | Interferon alfa receptor (IFNAR); COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Virology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Interferon alfa-1b is a recombinant interferon that activates natural killer cells and macrophages to enhance antiviral immunity and has immunomodulatory properties. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain. The combination aims to leverage both immune activation and symptomatic relief.
Approved indications
- Viral infections (specific indication not clearly documented in available sources)
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Gastrointestinal upset
- Headache
- Myalgia
Key clinical trials
- A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INF1.0 + IBU CI brief — competitive landscape report
- INF1.0 + IBU updates RSS · CI watch RSS
- St. Justine's Hospital portfolio CI
Frequently asked questions about INF1.0 + IBU
What is INF1.0 + IBU?
How does INF1.0 + IBU work?
What is INF1.0 + IBU used for?
Who makes INF1.0 + IBU?
What drug class is INF1.0 + IBU in?
What development phase is INF1.0 + IBU in?
What are the side effects of INF1.0 + IBU?
What does INF1.0 + IBU target?
Related
- Drug class: All Interferon alfa + NSAID combination drugs
- Target: All drugs targeting Interferon alfa receptor (IFNAR); COX-1 and COX-2
- Manufacturer: St. Justine's Hospital — full pipeline
- Therapeutic area: All drugs in Immunology / Virology / Pain Management
- Indication: Drugs for Viral infections (specific indication not clearly documented in available sources)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing